Media
The next phase of radioligand therapies is about execution
Pharma Manufacturing | January 6th, 2026
Manufacturers face growing pressure to align drug design, production strategy, logistics, and workforce planning to ensure reliable, at-scale delivery.
Engineering Next-Gen Radiopharmaceuticals for Precision and Safety
Clinical Edge Talks | October 30th, 2025
Radiopharmaceuticals have emerged as one of the most transformative modalities in oncology.
Navigating Complexity: Strategies to Accelerate Modern Clinical Trials
Applied Clinical Trials | August 5th, 2025
As clinical trials become more complex, success depends on early collaboration, thoughtful protocol design, and practical strategies to manage risk, reduce delays, and support patients.
Ratio, Ionetix ink separate deals to speed production of in-demand radiopharmaceutical isotopes
Fierce Pharma | June 23rd, 2025
Ratio Therapeutics and Ionetix have inked separate deals to boost production of the much-needed radioisotope actinium-225, which is helping fuel the explosive growth of radiopharmaceuticals in cancer treatment.
Ratio Therapeutics secures isotope supply deal with Nusano for radiopharmaceutical development
DOTMed HealthCare Business | June 23rd, 2025
Ratio Therapeutics has signed a long-term supply agreement with Nusano to secure commercial-scale access to several key medical isotopes used in cancer imaging and treatment.
Ratio Therapeutics awarded state incentive for WVC plant
Salt Lake Business Journal | June 21st, 2025
A Boston-based company that produces radiotherapies for cancer treatment and monitoring will get state help in building a manufacturing facility in West Valley City.
3 industry partnerships, 1 clinical aim: Enriching the global supply chain of medical isotopes
Health Imaging | June 19th, 2025
Nuclear medicine operations may soon enjoy steadier flows of certain in-demand radioisotopes. If so, much credit will go to companies that had the strategic sense to collaborate with other suppliers working the same or similar territories.
Ratio inks deal to build radiopharmaceutical R&D, manufacturing facility in Utah
Fierce Pharma | May 13th, 2025
Ratio Therapeutics, which specializes in the growing field of radiopharmaceuticals, has inked a deal to build a new research and manufacturing facility in Salt Lake City, Utah
How Radiopharmaceuticals Are Revolutionizing Cancer Therapy
Technology Networks | April 15th, 2025
Radiopharmaceuticals are transforming cancer care, offering hope for safer, smarter treatments.
New Approaches in Radiopharmaceutical Development
Journal of Nuclear Medicine | February 13th, 2025
John Babich talks with Lale Kostakoglu about current and coming trends in diagnostics and therapeutics.
Radiopharmaceutical deals drive sector growth despite supply crisis
Pharmaceutical Technology | February 5th, 2025
Developers celebrate gains for advances with radiopharmaceuticals while regulators and isotope suppliers work to keep up.
Podcast: Pre-JPM Biotech Dealmaking Panel
Citeline-In Vivo | January 10th, 2025
As we enter 2025, In Vivo convened a group of biotech executives for a wide-ranging conversation about dealmaking this year and the challenges and opportunities for companies in the cardiometabolic, longevity, radiopharmaceuticals and cancer spaces. Essential listening before JPM.
Attacking Cancer Targets with Radiotherapeutics
The Scientist | January 8th, 2025
John Babich from Ratio Therapeutics explains how radiopharmaceuticals can be designed to better treat cancer, alone and in combination with immunotherapies.
Where the Ratio deal fits into Novartis’ radiopharma matrix
BioCentury | November 19th, 2024
The deal grows Novartis’ ligand modality and chelator toolbox, and its focus on Lutathera target SSTR2.
Ratio Nets Potential $750M Radioligand Cancer Deal with Novartis
Inside Precision Medicine | November 19th, 2024
Novartis and Ratio to progress next-gen radiotherapeutic
European Pharmaceutical Review | November 19th, 2024
The collaboration between Novartis Pharma AG and Ratio Therapeutics aims to advance a potential best-in-class therapeutic candidate as a treatment for a difficult-to-treat cancer.
Novartis strengthens radiopharma leadership with Ratio Therapeutics deal
Pharmaceutical Technology | November 19th, 2024
Novartis has teamed up with Ratio Therapeutics in a $745m licensing and collaboration agreement to advance radiopharmaceutical therapies.
Novartis Invests $745M to Compete with BMS and Lilly in the Radiopharma Race
GeneOnline | November 19th, 2024
The deal gives Novartis the opportunity to collaborate with Ratio Therapeutics on a novel drug that could strengthen its position against radiopharmaceutical rivals like BMS and Lilly.
Ratio enters license, collaboration agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate
Medical Dialogues | November 19th, 2024
Ratio enters license, collaboration agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate.
Novartis drops up to $745M to move deeper into competitive radiopharma space
PharmaLive | November 18th, 2024
Novartis has struck a deal worth up to $745 million with Ratio Therapeutics for a radiopharmaceutical that could help defend its franchise from would-be challengers including Bristol Myers Squibb and Eli Lilly.
Novartis, Ratio to collaborate on SSTR2 radiotherapeutic for cancer
Seeking Alpha | November 18th, 2024
Novartis (NYSE:NVS) has entered into an exclusive worldwide license and collaboration agreement with Ratio Therapeutics for the development of a SSTR2 radiotherapeutic candidate for the treatment of cancer.
Novartis Expands Radiopharmaceutical Portfolio with $745M Deal with Ratio Therapeutics
Biopharma Trend | November 18th, 2024
Novartis has struck a licensing agreement with Boston-based biotech Ratio Therapeutics, securing global rights to a promising cancer candidate targeting somatostatin receptor 2 (SSTR2). The deal, announced on November 18, 2024, is valued at up to $745 million, including upfront and potential milestone payments, alongside royalties.
Novartis inks $745M radiopharma partnership with Ratio Therapeutics
MM+M | November 18th, 2024
Novartis will research a radiopharmaceutical drug that targets the somatostatin receptor 2 (SSTR2) in cancer with the help of Ratio’s expertise.
Ratio Therapeutics, Novartis Pharma Partner to Develop Radiotherapeutic Candidate for Cancer
RTT News | November 18th, 2024
Ratio Therapeutics Inc. Monday announced partnership with Novartis Pharma AG, a unit of Novartis AG (NVS) to develop a radiotherapeutic candidate for cancer.
Novartis partners with Ratio on SSTR2 therapy
Pharma Manufacturing | November 18th, 2024
Novartis has entered an exclusive license and collaboration agreement with Ratio Therapeutics to develop a Somatostatin Receptor 2 (SSTR2)-targeting radiotherapeutic candidate for cancer.
Novartis ramps up in radiopharma, and Eli Lilly adds Zepbound details
STAT | November 18th, 2024
Novartis Drops Up to $745M to Move Deeper Into Competitive Radiopharma Space
BioSpace | November 18th, 2024
The deal has secured Novartis the chance to work with Ratio Therapeutics on a novel drug candidate that could fortify the Big Pharma against competition from would-be radiopharmaceutical rivals such as BMS and Lilly.
Novartis signs deal with Mass. company worth up to $745M
Boston Business Journal | November 18th, 2024
Novartis’ interest in the hot area of radiopharmaceuticals is once again bringing it into contact with a Massachusetts company.
Novartis, Ratio sign radiopharmaceutical pact to the tune of $745M biobucks
Fierce Biotech | November 18th, 2024
Novartis is adding another radiopharmaceutical program to its collection, penning a deal worth $745 million in biobucks for rights to a cancer candidate from Ratio Therapeutics.
Novartis strikes radiopharma deal with Ratio worth up to $745M
Endpoints News | November 18th, 2024
Novartis is making another pact in radiopharma, promising as much as $745 million to a Boston-based startup.
What Immuno-Oncologists Need to Know About Radiopharmaceuticals
IO360 | October 23rd, 2024
Radiopharmaceuticals are emerging as a powerful avenue for treating cancer, and Ratio Therapeutics’ CEO and CSO talk specifically how the therapy can combine with immuno-oncology to enhance activity and efficacy, for patient benefit.
How a radiopharma up-and-comer builds momentum in a surging space
PharmaVoice | September 17th, 2024
Big Pharma is embracing the radiopharmaceuticals boom that was a long time in the making.
Advancing Radiopharmaceuticals: Targeting Strategies and Isotope Selection in Cancer Therapy – John Babich
UroToday | August 9th, 2024
John Babich discusses the potential of radiopharmaceuticals in cancer treatment. He emphasizes the importance of targeting and retention in tumor tissues, explaining the concept of therapeutic index and the company’s “radioligand first, isotope second” approach. Dr. Babich highlights their work on FAP (fibroblast activation protein) and their Trillium technology, which aims to optimize drug delivery by modulating pharmacokinetics. He discusses the challenges and opportunities in isotope selection, imaging, and target identification. Looking ahead, Dr. Babich predicts advancements in clinical utility, combination therapies, and target discovery for radioligand therapies. He also anticipates developments in chelation technology and heterodimeric molecules targeting multiple receptors.
Dr. Jack Hoppin & Dr. John Babich – Ratio Therapeutics – Best-In-Class Targeted Radiotherapeutics
Progress, Potential, and Possibilities | May 28th, 2024
Ratio Therapeutics on BMS Investment, Radiopharma R&D Trends, AI Use
Citeline | April 15th, 2024
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip.
BMS- backed radiopharma specialist Ratio expands manufacturing deal with CDMO Pharmalogic
Fierce Pharma | March 18th, 2024
Ratio Therapeutics, which develops radiotherapeutics, and CDMO PharmaLogic, which specializes in manufacturing them, have expanded their partnership.
Radiopharmaceuticals: The Resurgence and Future of Precision Oncology
Medriva | March 1st, 2024
The realm of oncology is witnessing a paradigm shift, with radiopharmaceuticals emerging as a beacon of hope for personalized cancer treatment. This innovative approach, combining radioactive substances with pharmaceuticals, is not just a fleeting trend but a resurgence of a method that dates back to the 1940s. Today, with the advent of theranostics—the fusion of diagnostics and therapeutics—radiopharmaceuticals are poised to redefine cancer care.
Why is pharma going gaga for Radiopharmaceuticals?
Pharmaphorum | February 27th, 2024
The pharma industry is always on the lookout for new therapeutic angles that might prove to be a competitive advantage. Ben Hargreaves outlines how oncology is a priority for research, and how radiopharmaceuticals are one of the major new interest areas.
Precision Radiopharmaceuticals with Ratio’s Jack Hoppin, Ph.D.
Bioprocess Online | February 26th, 2024
Multimodal approaches to the delivery of radiologically active compounds have created a fertile environment for players in the space to put on a precision medicine clinic, so to speak. What’s more, Radiopharmaceuticals create a unique business opportunity given the closely related and necessary companion diagnostic arena.
Tech, Media & Telecom Roundup: Market Talk
The Wall Street Journal | January 19th, 2024
The latest Market Talks covering Technology, Media, and Telecom.
The Week’s 10 Biggest Funding Rounds: Quantinuum and Flexport Lock Up Huge Rounds
Crunchbase News | January 19th, 2024
This is a weekly feature that runs down the week’s top 10 announced funding rounds in the U.S.
BridgeBio raises $1.25bn, and other biotech financings
Pharmaphorum | January 19th, 2024
Our round-up of recent biotech financings is headed by a massive $1.25 billion round for genetic medicines specialist BridgeBio Pharma, with smaller rounds for Tr1X, Comanche Biopharma, Ratio Therapeutics, and Myrobalan Therapeutics.
Early-stage funding roundup: Biopharma and biotech startups bagged 40% of the funding
Inside | January 19th, 2024
Ratio Therapeutics Raises $50M in Series B Financing
FinSMEs | January 18th, 2024
Ratio Therapeutics, a Boston, MA based pharmaceutical company, raised $50M in Series B funding.
Ratio Therapeutics secures funds for cancer radiotherapies
Pharmaceutical-Technology.com | January 18th, 2024
The investment will accelerate the clinical development of a fibroblast activation protein-alpha (FAP)-targeted radiopharmaceutical therapeutic.
More money moves into growth area of radiopharmaceuticals
The Pharma Letter | January 18th, 2024
Boston, USA-based Ratio Therapeutics has completed a $50 million series B financing, bringing the total raised by the company so far to over $90 million.
Ratio Therapeutics Scores $50M Series B
AlphaMaven | January 17th, 2024
Ratio Therapeutics announces the close of its $50M Series B financing.
Ratio Therapeutics Raises $50M in Series B Financing
Precision Medicine Online | January 17th, 2024
Ratio Therapeutics Announces $50M Series B Financing to Advance Targeted Radiotherapies for Cancer Treatment
DC News Now | January 17th, 2024
Boston-Based Radiopharmaceutical Company Brings Total Financing to More Than $90M Since 2021 Launch.
Ratio Therapeutics Scores $50M Series B
VC News Daily | January 17th, 2024
Ratio Therapeutics announces the close of its $50M Series B financing.
Boston’s Ratio Therapeutics Raises $50M Series B For R&D
Law360 | January 17th, 2024
Pharmaceutical startup Ratio Therapeutics has raised a fresh round of funding, the company announced Wednesday, closing on a $50 million Series B round that will be used to expand its research and development platforms and advance a treatment to clinical trials.
Fierce Biotech Fundraising Tracker ’24: Comanche adds $75M for preeclampsia med; Ratio entices BMS
Fierce Biotech | January 17th, 2024
A new year means a new Fierce Biotech Fundraising Tracker to record all the venture capital being funneled into the industry for 2024.
Ratio Therapeutics raises $50M for tumor-targeting radiopharmaceuticals
Boston Business Journal | January 17th, 2024
The Boston company has secured the backing to move its first therapeutic candidate into clinical trials by the of this year.
Ratio raises $50M as radiopharma field finds its groove
Endpoints News | January 17th, 2024
Radiopharmaceutical biotech Ratio Therapeutics has raised a $50 million Series B to bring its first therapeutic into the clinic, it said Wednesday morning.
In the fight against cancer, it’s boom times for radiopharmaceuticals
STAT | November 8th, 2023
Targeting tumours with novel radiopharmaceuticals
European Pharmaceutical Review | October 19th, 2023
In this exclusive Q&A, Dr Jack Hoppin, CEO, and Dr John Babich, Chief Scientific Officer of Ratio Therapeutics share their perspective on the evolving radiopharmaceutical landscape and why radiopharmaceutical therapeutics have significant potential in oncology.
Developing Best-in-Class Radiopharmaceuticals for Cancer Patients
Rx for Biotech | September 19th, 2023
Our guests for this podcast episode are the co-founders of Ratio Therapeutics, CEO Jack Hoppin, PhD, and Chief Scientific Officer, John Babich, PhD. Ratio Therapeutics’ mission is to develop best-in-class radiopharmaceuticals for the treatment of cancers.
Health Innovators- Dr. Jack Hoppin and Dr. John Babich (follow-up)
Pharmaphorum | August 17th, 2023
The last time we checked in on Ratio Therapeutics co-founders Dr. Jack Hoppin and Dr. John Babich, they were working out of a WeWork co-working space in downtown Boston, just beginning their work with targeted radiotherapeutics and mathematical modeling.
Radiopharmaceuticals for cancer: Making radiation precise
BioPharma Dive | August 15th, 2023
More than a dozen startups are developing drugs that deliver a dose of radiation directly to tumors. Here’s where they stand, and why their progress is worth watching.
Ratio Therapeutics announces first patient dosed in FAP-targeted radiopharmaceutical study
BioPharma Reporter | July 31st, 2023
Boston-based pharma company Ratio Therapeutics has initiated dosing in a phase 1 study evaluating the pharmacokinetics, biodistribution and radiation dosimetry of a novel fibroblast activation protein-alpha (FAP)- targeted radiopharmaceutical, RTX-1363S, for PET imaging in adult healthy volunteers.
Treating Cancer using Targeted Radiotherapeutics with Jack Hoppin and John Babich of Ratio Therapeutics
From Launch to Lab by Qualio | July 26th, 2023
Today we have Dr. Jack Hoppin CEO of Ratio Therapeutics and Dr. John Babich Chief Science Officer of Ratio Therapeutics. The team at Ratio Therapeutics is developing a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers. They recently opened a 19,000-square-foot headquarters and R&D facility in Boston to continue their exciting innovation.
Ratio: tuning the pharmakokinetics of radiotherapies
BioCentury | June 30th, 2023
The company’s Trillium platform combines the tumor penetration of small molecules with the staying power of mAbs for its actinium-225 therapies.
The dawn of the interim CFO
CFO Dive | May 16th, 2023
With financial leadership coming at a premium, interim CFOs are having their moment in the spotlight.
Ratio Therapeutics unveils new research and development facility
BioPharma Reporter | May 15th, 2023
Boston-based radiopharmaceutical company Ratio Therapeutics has opened a new 19,000 square foot headquarters and R&D facility.
Radiopharmaceuticals on their way to becoming mainstream cancer therapies
BioWorld | April 3rd, 2023
The big idea behind radiopharmaceuticals is taking the hallmarks of two cancer therapies – radiology and chemotherapy – and merging them, and this is what makes the technology a disrupter.
FDA Guiding Industry to Optimize Cancer Drug Dosing in Precision Oncology Era
Precision Oncology News | March 28th, 2023
In releasing a draft guidance earlier this year on dose optimization for cancer therapies, the US Food and Drug Administration is steadily advancing its decades-long campaign to move the industry away from the default use of a maximum-tolerated dosing paradigm in clinical trials and toward a more patient-centered approach.
Ratio To Fine-Tune Radioligand Approach In Cancer With Trillium and Macropa Platforms
SCRIP | March 10th, 2023
The US biotech’s Trillium platform, which has caught the eye of Bayer, could enhance radioligand pharmacokinetics and bioavailability while reducing side effects, enabling the development of both therapeutics and imaging compounds.
#325- Jack Hoppin and John Babich of Ratio Therapeutics
Slice of Healthcare | March 6th, 2023
Our Guests: Jack Hoppin, Chairman & CEO at Ratio Therapeutics and John Babich, Director, President & CSO at Ratio Therapeutics.
Ratio Therapeutics CFO gets due-diligence ready
CFO Dive | February 9th, 2023
The biotech firm’s new CFO wants to make sure the young company is always able to answer questions potential investors may have.
Ratio Therapeutics Raises $20M in Series A Financing
Precision Oncology News | February 2nd, 2023
Ratio Therapeutics on Wednesday announced that it has raised $20 million in a Series A financing round, which it plans to put toward developing its targeted radiotherapeutics for patients with solid tumors.
Tunable Radio Pharmaceuticals? The Founders of Ratio Therapeutics
BioTechIQ Podcast | Janurary 6th, 2023
Throughout many of the discussions on BioTech IQ it is clear that a combination of therapies is likely the answer to treating cancers and other diseases. This is a point well made by the guests on this episode of the show. CEO Jack Hoppin, PhD and Chief Scientific Officer, John Babich PhD are Co-Founders of Ratio Therapeutics. Both bring a successful background in biotech and not only discuss what their organization is doing but lessons they have learned as entrepreneurs in treatment development.
Ratio Therapeutics CDO: “Part of Our Data Team’s Role is Being an Ambassador”
CDO Magazine | December 12th, 2022
Jacob Hesterman, Ratio Therapeutics Chief Data Officer, speaks with Kiran Kanetkar, Pendulum Therapeutics VP of Data and Analytics and CDO Magazine Global Editorial Board Member, in a video interview about the importance of data and analytics in modern drug discovery research, handling data literacy and self-service, and balancing the need for buying and building tools.
Health Innovators- Dr. Jack Hoppin and Dr. John Babich
Pharmaphorum | December 9th, 2022
A few weeks ago, pharmaphorum Editor-in-Chief Jonah Comstock popped in on Ratio Therapeutics co-founders Dr. Jack Hoppin and Dr. John Babich at their WeWork coworking space in downtown Boston for a Health Innovators interview.
Building New Solutions For 2023 In Manufacturing And Supply Chain
Life Science Leader | December 1st, 2022
Manufacturing and scaling the spate of new advanced therapeutics in development will continue to present a challenge in 2023, particularly as key supplies and ingredients remain sluggish to procure. Even so, biopharmaceutical executives contributing to this year’s industry outlook evince a confidence about the solutions they have devised from their respective perches along the value chain. In the following Q&A, 11 executives provide their thoughts on what the future holds for biopharmaceutical manufacturing and supply chain operations, and which issues will have the most impact.
Ratio Therapeutics: Math Meets Medicine in the Design of Radiotherapies
Hopkins Biotech Podcast | November 20th, 2022
Ratio Therapeutics is a Boston-based pharmaceutical company with the mission to accelerate the development of best-in-class targeted radiotherapeutics for the treatment of cancers. By employing a suite of innovative technologies the company is developing innovative and proprietary Pharmacokinetics (PK) Modulation technology for the construction of improved therapeutic agents and transforming oncology treatment paradigms.
Ratio Therapeutics CDO: It’s Rewarding to Ingest Disparate Data in a Structured Way
CDO Magazine | November 1st, 2022
Jacob Hesterman, Ratio Therapeutics Chief Data Officer, speaks with Kiran Kanetkar, Pendulum Therapeutics VP of Data and Analytics and CDO Magazine Global Editorial Board Member, in a video interview about the role of data and analytics in the radiotherapy industry and the approach to managing multidisciplinary data.
Ratio Therapeutics with FAPI and more Audio
The Nuclear Medicine and Molecular Medicine Podcast | October 18th, 2022
We talk with a new company that is harnessing theranostics with ligands we have discussed before.
Targeting and Deploying Optimum Radiopharmaceuticals to Treat Cancer with Jack Hoppin and John Babich Ratio Therapeutics
The Empowered Patient Podcast | September 27th, 2022
Jack Hoppin Ph.D. Chief Executive Officer and John Babich Ph.D., President and Chief Scientific Officer, and Co-Founders of Ratio Therapeutics aim to develop and produce best-in-class radiopharmaceuticals. Harnessing the power of radiation by making it into an injectable drug, Ratio is creating a way to find tumor cells anywhere in the body.
Ratio Therapeutics emerges with $20M financing, taking mathematical approach to radiopharmaceuticals
BioWorld | June 20th, 2022
In the last decade, Bayer AG and Novartis AG have shown that radiopharmaceutical technology can produce marketable drugs, with Xofigo (radium-223 dichloride) and Lutathera (lutetium [177Lu] oxodotreotide), respectively approved for prostate cancer and neuroendocrine tumors.
The Petri Dish: Amylyx, Alnylam net drug approvals
Boston Business Journal | June 16th, 2022
The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more. Here’s The Petri Dish, a roundup of news that may get overlooked amid the influx of health care happenings.
Ratio Therapeutics Launches to Develop More Target-Specific, Less Toxic Radiopharmaceuticals
Precision Oncology News | June 16th, 2022
Ratio Therapeutics officially launched last week hoping to differentiate itself in the crowded targeted radiopharmaceutical space through technology it believes can home in on tumor tissue and spare toxicity to normal cells better than competitors.